Literature DB >> 11569188

[Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone].

N I Kurysheva, A A Shpak, E E Ioĭleva, L I Galanter, N D Nagornova, N Iu Shubina, N N Shlyshalova.   

Abstract

A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients with normalized ophthalmic tone. Electrophysiological and computer methods of examination demonstrated the advantages of new therapy over traditional neuroprotective treatment for glaucoma. The efficiency is due to pathogenetic activity of semax possessing both neuroprotective and neurotrophic effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11569188

Source DB:  PubMed          Journal:  Vestn Oftalmol        ISSN: 0042-465X


  2 in total

1.  Expression changes caused by the peptide semax in the intracellular signal pathway genes in rat hippocamp.

Authors:  T Yu Agapova; Ya V Agniullin; D N Silachev; M I Shadrina; P A Slominsky; S I Shram; S A Limborskaya; N F Myasoedov
Journal:  Dokl Biochem Biophys       Date:  2007 Nov-Dec       Impact factor: 0.788

2.  Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action.

Authors:  Maria Shadrina; Timur Kolomin; Tamara Agapova; Yan Agniullin; Stanislav Shram; Petr Slominsky; Svetlana Lymborska; Nikolay Myasoedov
Journal:  J Mol Neurosci       Date:  2009-08-07       Impact factor: 3.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.